Fosfomycin: Targeted Urinary Tract Infection Relief
| Product dosage: 3g | |||
|---|---|---|---|
| Package (num) | Per sachet | Price | Buy |
| 1 | $42.38 | $42.38 (0%) | 🛒 Add to cart |
| 2 | $37.84 | $84.77 $75.68 (11%) | 🛒 Add to cart |
| 3 | $35.99 | $127.15 $107.98 (15%) | 🛒 Add to cart |
| 4 | $35.32 | $169.53 $141.28 (17%) | 🛒 Add to cart |
| 5 | $34.92 | $211.91 $174.58 (18%) | 🛒 Add to cart |
| 6 | $34.48 | $254.30 $206.87 (19%) | 🛒 Add to cart |
| 7 | $34.31 | $296.68 $240.17 (19%) | 🛒 Add to cart |
| 8 | $34.18 | $339.06 $273.47 (19%) | 🛒 Add to cart |
| 9 | $33.97 | $381.45 $305.76 (20%) | 🛒 Add to cart |
| 10 | $33.91
Best per sachet | $423.83 $339.06 (20%) | 🛒 Add to cart |
Synonyms | |||
Fosfomycin is a bactericidal antibiotic with a unique chemical structure and mechanism of action, offering a distinct therapeutic profile for uncomplicated urinary tract infections (UTIs). As a phosphonic acid derivative, it inhibits bacterial cell wall synthesis at an early stage by targeting the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), rendering it effective against both gram-positive and gram-negative uropathogens. Its high urinary concentration and minimal systemic absorption make it a valuable option for focused antimicrobial therapy, particularly in an era of increasing antibiotic resistance. This agent is available in oral formulation as fosfomycin tromethamine, providing convenience and compliance advantages in outpatient management.
Features
- Chemical class: Epoxy phosphonic acid antibiotic
- Mechanism: Irreversible inhibition of MurA, preventing peptidoglycan synthesis
- Formulation: Fosfomycin tromethamine salt for enhanced oral bioavailability
- Spectrum: Broad activity against common uropathogens including E. coli, Enterococcus faecalis
- Resistance profile: Low cross-resistance with other antibiotic classes
- Pharmacokinetics: Rapid urinary excretion with minimal systemic absorption
- Administration: Single-dose sachet formulation (3g fosfomycin tromethamine)
Benefits
- Single-dose regimen enhances patient compliance and reduces treatment abandonment
- Maintains efficacy against multidrug-resistant organisms including ESBL-producing Enterobacteriaceae
- Favorable safety profile with minimal disruption to gut microbiota compared to prolonged courses
- Suitable for patients with penicillin allergies due to distinct chemical structure
- Rapid bactericidal action achieves therapeutic urinary concentrations within 2-4 hours
- Lower risk of Clostridium difficile infection compared to broader-spectrum alternatives
Common use
Fosfomycin tromethamine is primarily indicated for the treatment of uncomplicated urinary tract infections (acute cystitis) in women caused by susceptible strains of Escherichia coli and Enterococcus faecalis. It is particularly valuable in cases where first-line agents are contraindicated or ineffective due to resistance patterns. The drug may also be used off-label for prophylaxis in recurrent UTIs or for complicated UTIs when guided by susceptibility testing. Its role in male UTIs or pediatric populations requires careful consideration and is generally not first-line without specific indications.
Dosage and direction
The standard adult dosage for uncomplicated UTIs is a single 3 gram sachet of fosfomycin tromethamine dissolved in ½ glass (4 ounces) of cold water. Administration should occur immediately after dissolution, preferably at bedtime with an empty bladder to maximize urinary concentration and contact time. For patients with renal impairment (CrCl <50 mL/min), dosage adjustment may be necessary, though specific guidelines vary. Repeat dosing is generally not recommended within 48 hours without medical supervision. The powder should not be taken in dry form and requires complete dissolution before ingestion.
Precautions
Use with caution in patients with severe renal impairment (CrCl <10 mL/min) due to reduced urinary excretion. Monitor for superinfection or fungal overgrowth with prolonged or repeated use. Diarrhea may occur and could represent pseudomembranous colitis. Avoid concomitant medications containing metoclopramide as they may decrease urinary concentrations. Pregnancy Category B: use only if clearly needed after risk-benefit assessment. Breastfeeding considerations: minimal systemic absorption suggests low risk, but caution advised. Elderly patients may require monitoring for electrolyte imbalances.
Contraindications
Hypersensitivity to fosfomycin or any component of the formulation. Severe renal impairment with inadequate urinary output. Concomitant use with drugs that significantly decrease gastrointestinal motility. Not recommended for patients with anatomical urinary obstructions or functional impairment that prevents adequate voiding. Should not be used for systemic infections due to limited tissue penetration. Avoid in patients with history of severe gastrointestinal diseases affecting absorption.
Possible side effect
Common: diarrhea (9%), nausea (4%), headache (3%), vaginitis (2%). Less common: dizziness, dyspepsia, abdominal pain, rash. Rare: eosinophilia, thrombocytopenia, elevated liver enzymes, anaphylactic reactions. Pseudomembranous colitis may occur during or after treatment. Cases of drug fever and eosinophilic pneumonia have been reported. Most adverse effects are mild and self-limiting given the single-dose regimen.
Drug interaction
Metoclopramide: decreases urinary concentration of fosfomycin. Antacids containing magnesium or calcium: may reduce absorption. Probenecid: may decrease urinary excretion. Oral contraceptives: theoretical interaction possible, recommend backup method. No significant interactions with warfarin documented, but monitor INR with concomitant use. Caution with other nephrotoxic drugs in patients with renal impairment.
Missed dose
As fosfomycin is typically administered as a single dose, missed dose scenarios are uncommon. If a patient fails to take the medication at the prescribed time, it should be taken as soon as remembered unless it is near the time for the next dose. Do not double doses. For prophylactic regimens using repeated dosing, consult prescribing physician for specific guidance based on timing and indication.
Overdose
No specific antidote exists. Symptoms may include gastrointestinal distress, diarrhea, or electrolyte imbalances. Management is supportive with attention to hydration status and electrolyte correction. Hemodialysis may remove fosfomycin (40-50% efficiency) in cases of significant overdose with renal impairment. Contact poison control center for latest guidance. No cases of fatal overdose have been reported in clinical literature.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Keep sachet in original packaging until use. Protect from moisture and excessive heat. Do not freeze the powder or prepared solution. Keep out of reach of children. Discard any unused portion of dissolved medication. Do not use if packaging is damaged or powder shows signs of moisture absorption.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional for diagnosis and treatment decisions. The prescribing physician should be aware of local resistance patterns when selecting antimicrobial therapy. Dosage and indications may vary based on regional guidelines and patient-specific factors. Not all possible interactions or side effects are listed here.
Reviews
Clinical studies demonstrate efficacy rates of 70-90% for uncomplicated UTIs caused by susceptible organisms. Many experts appreciate its role as a resistance-sparing agent. Patient satisfaction surveys indicate high compliance due to single-dose convenience. Some reviews note lower efficacy rates compared to longer-course therapies for certain pathogens. Increasing resistance in some geographic regions requires ongoing susceptibility monitoring. Overall considered a valuable option in the antimicrobial arsenal when used appropriately.